Locally Advanced Thymoma
Conditions
Keywords
neoadjuvant radiotherapy, Locally Advanced Thymoma, neoadjuvant chemoradiotherapy
Brief summary
The goal of this prospective, randomized, controlled phase II clinical study is to evaluate the efficacy and safety of neoadjuvant radiotherapy in patients with locally advanced unresectable thymoma. The main questions it aims to answer are: 1. Which treatment method is more effective in improving the radical resection rate: neoadjuvant chemoradiotherapy or neoadjuvant radiotherapy ? 2. The safety and adverse reactions of neoadjuvant radiotherapy? Does the addition of neoadjuvant chemotherapy have an impact on this? Participants will be randomly divided into two groups: one group will receive neoadjuvant radiotherapy, and the other will receive neoadjuvant chemoradiotherapy. The primary endpoint of the study is to evaluate the radical resection rate (R0) of two groups. The secondary endpoints will include the pathological complete response rate (pCR), 3-year progression-free survival, and safety and toxicities. In addition, this study will explore the feasibility and completion rate of minimally invasive surgical resection.
Detailed description
For patients with thymoma, surgery is the optimal choice, and it has been proven to improve the survival rate of patients with thymoma. For locally advanced unresectable thymoma, direct surgical resection is associated with significant trauma, a high incidence of surgical complications, and a risk of postoperative recurrence. The application of neoadjuvant therapy is expected to reduce tumor volume and downstage the tumor, thereby increasing the rate of complete tumor resection (R0). Clinical practice has confirmed that thymic tumors are sensitive to both radiotherapy and chemotherapy. However, neoadjuvant chemotherapy regimens for thymoma have not been unified, and the available evidence recommends cisplatin based combination regimens. Earlier retrospective studies mainly targeting locally advanced unresectable thymoma suggested that neoadjuvant radiotherapy could achieve an R0 resection rate of about 50%-75% in these patients. In recent years, neoadjuvant chemoradiotherapy has shown promise in terms of objective response rate and R0 resection rate in patients with thymoma. There is still controversy over how to choose an appropriate neoadjuvant treatment protocol for such patients, and there is a lack of randomized prospective controlled studies. In this prospective randomized controlled study, participants will be randomly assigned in a 1:1 ratio into two groups. One group will receive neoadjuvant radiotherapy alone, while the other group will receive the same radiotherapy regimen in combination with concurrent cisplatin chemotherapy. Participants in both groups will undergo standard surgery based on efficacy assessment. The purpose of this study is to evaluate the impact of these two approaches on the R0 resection rate in patients and to comprehensively assess the safety of the treatment modalities. This study also aims to provide clinical evidence for neoadjuvant treatment strategies in locally advanced unresectable thymoma.
Interventions
RADIATIONneoadjuvant radiotherapy
Target the primary tumor region with 40-50 Gy in 20-25 fractions.
DRUGcisplatin
The cisplatin will be given concurrently with radiotherapy (25 mg/m² , D1, QW) for 4-5 cycles.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Aged ≥18 years and ≤75 years. * Histologically confirmed thymoma of Masaoka-Koga stage III-IV A. * Assessed as unresectable thymoma by a thoracic surgeon prior to treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * No prior anti-thymoma treatment, including but not limited to systemic chemotherapy, radiotherapy, surgery, or immunotherapy. * Presence of at least one measurable lesion according to RECIST v1.1 criteria. * Cardiopulmonary function compatible with surgery. * Expected survival of \>3 months. * Comprehensive evaluation completed within 28 days before enrollment in the study, with a full blood cell test obtained within 15 days, demonstrating normal visceral organ function and normal bone marrow function. * Negative serum or urine pregnancy test for women of childbearing potential within 14 days before study enrollment. * Willingness of the patient to sign an informed consent form and to adhere to the specified follow-up schedule.
Exclusion criteria
* Histologically confirmed thymic neuroendocrine tumor. * Currently participating in an interventional clinical study that may affect this study, or having received other investigational drugs or devices within 4 weeks prior to the first treatment in this study. * Pregnant or breastfeeding women. * Previous history of thoracic radiotherapy. * Deemed unsuitable for three-dimensional conformal or intensity-modulated radiotherapy by a radiation oncology specialist. * History of allogeneic bone marrow or organ transplantation. * History of malignancies other than thymoma within the past 3 years, or untreated other primary malignancies. * Serious comorbidities that would affect the study treatment. * Any history or evidence of disease, treatment, or abnormal laboratory values that could interfere with the study results or prevent the participant from completing the study, or other situations deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radical resection rate（R0） | up to 1 year | The tumor lesion is completely resected, with no residual tumor visible to the naked eye at the surgical margins, and no cancer cells detectable at the margins under the microscope. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pCR rate | up to 1 year | ypT0N0 |
| PFS | up to 3 years | PFS measures the duration from the initiation of treatment to the point of disease progression, recurrence, or death from any cause. |
| Safety and toxicities | up to 3 years | Adverse events will be evaluated according to CTCAE v5.0 . |
Countries
China
Contacts
Primary ContactTing Zhang
Outcome results
None listed